News | October 25, 2021

Drug Delivery Veteran, Raj Khankari, Joins Kindeva Drug Delivery

Source: Kindeva Drug Delivery

St. Paul, MN – Kindeva Drug Delivery (Kindeva) announced that Dr. Raj Khankari has joined Kindeva’s Leadership Team as the Vice President, Research and Development. Dr. Khankari brings 28 years of global experience in the pharmaceutical and drug delivery sectors.

Dr. Khankari has held senior leadership roles at multiple organizations. Most recently, he was CEO at RiboCor, Inc., and prior to that served as the General Manager / Vice President of Worldwide Drug Delivery Technologies at CIMA Labs/Cephalon.

“Raj’s significant experience combining drug delivery technology development and business leadership make him an ideal fit for this key leadership position,” said Aaron Mann, CEO of Kindeva. “Since our separation from 3M in 2020, customers are asking Kindeva to help with ever more complex drug delivery programs, whether it is developing a more sustainable inhaled therapy, or formulating a drug for delivery via our microneedle-based platforms. Raj’s leadership will help advance all of these exciting programs, globally.”

“Kindeva’s R&D organization has a leading reputation built across many decades and many product approvals,” said Dr. Khankari. “I’m excited to help accelerate our growth in drug delivery across our technology platforms and geographies.”

Raj holds a Ph.D in Pharmaceutics and an MBA from the University of Minnesota, and a Masters in Pharmaceutics from the University of Cincinnati.

About Kindeva Drug Delivery

Headquartered in St. Paul, Minnesota, Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) in the pharmaceutical industry. Kindeva provides unique technologies and quality services to its customers, ranging from formulation and product development to commercial manufacturing. Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, microstructured transdermal systems (microsystems), and connected drug delivery. Kindeva employs approximately 1,000 people worldwide. For more information, visit www.kindevadd.com.

Source: Kindeva Drug Delivery